AR060432A1 - Tetrahidropteridinas utiles como inhibidores de las proteinas quinasas - Google Patents
Tetrahidropteridinas utiles como inhibidores de las proteinas quinasasInfo
- Publication number
- AR060432A1 AR060432A1 ARP070101560A ARP070101560A AR060432A1 AR 060432 A1 AR060432 A1 AR 060432A1 AR P070101560 A ARP070101560 A AR P070101560A AR P070101560 A ARP070101560 A AR P070101560A AR 060432 A1 AR060432 A1 AR 060432A1
- Authority
- AR
- Argentina
- Prior art keywords
- aliphatic
- independently
- cycloaliphatic
- halo
- optionally substituted
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 25
- 125000005843 halogen group Chemical group 0.000 abstract 8
- -1 -OH Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000002950 monocyclic group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000000565 sulfonamide group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79132706P | 2006-04-12 | 2006-04-12 | |
| US83872006P | 2006-08-18 | 2006-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060432A1 true AR060432A1 (es) | 2008-06-18 |
Family
ID=38544378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101560A AR060432A1 (es) | 2006-04-12 | 2007-04-12 | Tetrahidropteridinas utiles como inhibidores de las proteinas quinasas |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7763629B2 (enExample) |
| EP (1) | EP2010542B1 (enExample) |
| JP (1) | JP5313875B2 (enExample) |
| KR (1) | KR101432316B1 (enExample) |
| AR (1) | AR060432A1 (enExample) |
| AT (1) | ATE542823T1 (enExample) |
| AU (1) | AU2007238690B2 (enExample) |
| CA (1) | CA2649324A1 (enExample) |
| ES (1) | ES2381212T3 (enExample) |
| IL (1) | IL194699A (enExample) |
| MX (1) | MX2008013110A (enExample) |
| NO (1) | NO20084747L (enExample) |
| NZ (1) | NZ571969A (enExample) |
| RU (1) | RU2441006C2 (enExample) |
| TW (1) | TW200808805A (enExample) |
| WO (1) | WO2007120752A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008287339A1 (en) * | 2007-08-15 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases |
| BRPI0821209A2 (pt) | 2007-12-19 | 2019-09-24 | Amgen Inc | composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor. |
| US8389533B2 (en) | 2008-04-07 | 2013-03-05 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
| MX2011000021A (es) * | 2008-06-23 | 2011-02-24 | Vertex Pharma | Inhibidores de proteina cinasas. |
| CA2728729C (en) * | 2008-06-23 | 2016-09-27 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors |
| RU2012116526A (ru) * | 2009-09-25 | 2013-10-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы |
| EP2480550B1 (en) | 2009-09-25 | 2016-02-10 | Vertex Pharmaceuticals Incorporated | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| KR20120120252A (ko) | 2009-12-23 | 2012-11-01 | 엘란 파마슈티칼스, 인크. | 폴로-유사 키나제의 억제제로서의 프테리디논 |
| EP2535059A4 (en) | 2010-02-10 | 2014-03-12 | Public Univ Corp Yokohama City | USE OF A MSIN3B BINDING COMPOUND FOR SPECIFIC BINDING TO THE NEURONIC RESTRICTIVE SILENCER FACTOR (NRSF) |
| EP2588110B1 (en) | 2010-07-02 | 2018-10-17 | University Health Network | Methods of targeting pten mutant diseases and compositions therefor |
| CN103403010A (zh) * | 2010-10-08 | 2013-11-20 | 依兰制药公司 | Polo样激酶的抑制剂 |
| TW201307347A (zh) | 2010-11-01 | 2013-02-16 | Arqule Inc | 經取代苯並－咪唑並－吡啶並－二氮呯化合物 |
| PH12013501940A1 (en) | 2011-03-23 | 2015-12-04 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| MD4300C1 (ro) * | 2012-12-28 | 2015-03-31 | Государственный Университет Молд0 | Inhibitor al proliferării celulelor HepG2 în cancerul hepatic în bază de cloro-[2-fenil(piridin-2-il)metanon-4-(3-metoxifenil)tiosemicarbazono]nichel |
| WO2016183071A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Hetero-tricyclic compounds and their use for the treatment of cancer |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| JP7034084B2 (ja) | 2016-03-28 | 2022-03-11 | インサイト・コーポレイション | Ｔａｍ阻害剤としてのピロロトリアジン化合物 |
| CA3077308A1 (en) | 2017-09-27 | 2019-04-04 | Incyte Corporation | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
| EA202190153A1 (ru) | 2018-06-29 | 2021-04-09 | Инсайт Корпорейшн | Составы ингибитора axl/mer |
| CN109734809A (zh) * | 2019-02-27 | 2019-05-10 | 南方科技大学 | 治疗性的人Plk1蛋白单克隆抗体及其制备方法 |
| AU2021230385A1 (en) | 2020-03-06 | 2022-09-22 | Incyte Corporation | Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors |
| WO2023017442A1 (en) * | 2021-08-10 | 2023-02-16 | Uppthera, Inc. | Novel plk1 degradation inducing compound |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA973884B (en) * | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| CA2393896A1 (en) * | 1999-09-15 | 2001-03-22 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| CN1720224A (zh) * | 2002-10-03 | 2006-01-11 | 塔尔基公司 | 血管平衡剂及其使用方法 |
| KR20050056227A (ko) | 2002-10-03 | 2005-06-14 | 탈자진 인코포레이티드 | 혈관항상성 유지제 및 그의 사용 방법 |
| CA2528975A1 (en) | 2003-06-10 | 2004-12-16 | Pfizer Inc. | Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea |
| GB0315966D0 (en) * | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| GB0400700D0 (en) | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| GB0412874D0 (en) | 2004-06-09 | 2004-07-14 | Pfizer Ltd | Novel pharmaceuticals |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
-
2007
- 2007-04-12 ES ES07755318T patent/ES2381212T3/es active Active
- 2007-04-12 EP EP07755318A patent/EP2010542B1/en not_active Not-in-force
- 2007-04-12 WO PCT/US2007/009006 patent/WO2007120752A2/en not_active Ceased
- 2007-04-12 AT AT07755318T patent/ATE542823T1/de active
- 2007-04-12 MX MX2008013110A patent/MX2008013110A/es active IP Right Grant
- 2007-04-12 US US11/786,578 patent/US7763629B2/en not_active Expired - Fee Related
- 2007-04-12 RU RU2008144584/04A patent/RU2441006C2/ru not_active IP Right Cessation
- 2007-04-12 NZ NZ571969A patent/NZ571969A/en not_active IP Right Cessation
- 2007-04-12 AU AU2007238690A patent/AU2007238690B2/en not_active Ceased
- 2007-04-12 CA CA002649324A patent/CA2649324A1/en not_active Abandoned
- 2007-04-12 AR ARP070101560A patent/AR060432A1/es unknown
- 2007-04-12 KR KR1020087027593A patent/KR101432316B1/ko not_active Expired - Fee Related
- 2007-04-12 TW TW096112918A patent/TW200808805A/zh unknown
- 2007-04-12 JP JP2009505472A patent/JP5313875B2/ja not_active Expired - Fee Related
-
2008
- 2008-10-12 IL IL194699A patent/IL194699A/en not_active IP Right Cessation
- 2008-11-10 NO NO20084747A patent/NO20084747L/no not_active Application Discontinuation
-
2010
- 2010-06-08 US US12/796,174 patent/US8067417B2/en not_active Expired - Fee Related
-
2011
- 2011-10-05 US US13/253,196 patent/US8524902B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ571969A (en) | 2011-10-28 |
| WO2007120752A3 (en) | 2008-05-08 |
| CA2649324A1 (en) | 2007-10-25 |
| MX2008013110A (es) | 2009-03-06 |
| IL194699A0 (en) | 2009-08-03 |
| JP2009536155A (ja) | 2009-10-08 |
| EP2010542B1 (en) | 2012-01-25 |
| HK1134486A1 (en) | 2010-04-30 |
| JP5313875B2 (ja) | 2013-10-09 |
| US7763629B2 (en) | 2010-07-27 |
| NO20084747L (no) | 2008-11-25 |
| KR20080109919A (ko) | 2008-12-17 |
| ATE542823T1 (de) | 2012-02-15 |
| WO2007120752A2 (en) | 2007-10-25 |
| US8524902B2 (en) | 2013-09-03 |
| US8067417B2 (en) | 2011-11-29 |
| US20120277425A1 (en) | 2012-11-01 |
| RU2008144584A (ru) | 2010-05-20 |
| AU2007238690A1 (en) | 2007-10-25 |
| EP2010542A2 (en) | 2009-01-07 |
| KR101432316B1 (ko) | 2014-08-29 |
| RU2441006C2 (ru) | 2012-01-27 |
| US20090062292A1 (en) | 2009-03-05 |
| US20110021519A1 (en) | 2011-01-27 |
| AU2007238690B2 (en) | 2013-05-02 |
| IL194699A (en) | 2014-07-31 |
| TW200808805A (en) | 2008-02-16 |
| ES2381212T3 (es) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060432A1 (es) | Tetrahidropteridinas utiles como inhibidores de las proteinas quinasas | |
| AR059505A1 (es) | Dihidrodiazepinas utiles como inhibidores de proteina quinasas | |
| ES2657687T3 (es) | Derivados de pirrolopirimidina para uso en el tratamiento de infecciones virales | |
| ES2707885T3 (es) | Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades | |
| AR060316A1 (es) | Azaindoles de utilidad como inhibidores de janus quinasas | |
| ECSP055774A (es) | Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica | |
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| AR057712A1 (es) | Dihidropteridinonas en el tratamiento de enfermedades respiratorias | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| AR043885A1 (es) | Derivados de pirimidina | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| AR110051A2 (es) | Pirazolo[3,4-d]pirimidinas útiles para tratar trastornos respiratorios | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR060054A1 (es) | Inhibidores de c-met protein quinasas. composiciones farmaceuticas. | |
| AR070925A1 (es) | 4- hidroxipirimidina -5- carboxamida sustituidas, un procedimiento para el tratamiento preventivo de anemia, procedimiento para potenciar la produccion endogena de eritropoyetina, uso del compuesto en la fabricacion de un medicamento y composicion farmaceutica | |
| AR060957A1 (es) | Derivados de tiazolo-pirimidina / piridina-urea | |
| AR056347A1 (es) | Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| RU2008114378A (ru) | Производные 2-аминопиримидина как модуляторы активности н4-рецептора гистамина | |
| RU2008119435A (ru) | Производные триазолопиридина в качестве ингибиторов липаз и фосфолипаз | |
| AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
| AU2012210652B2 (en) | Use of nicotinic acetylcholine receptor alpha 7 activators | |
| BR112012020557A8 (pt) | formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio | |
| AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |